To learn more about our research department, or if you have any questions, please contact our Research Staff:
- Stacey Fisher, Clinical Research Coordinator, DM1
- Danielle Turner, Clinical Research Coordinator
- Michael Hill, Surgical Study Coordinator
Phone: 702-851-4672
Fax: 702-851-4670
Below is a partial list of current clinical trials with which the WCC is involved. To learn more, or to find other, related studies, please visit the NHI clinical trials website which features a searchable database.
GOG-0136 – Acquisition of Human Gynecologic Specimens and Serum to Be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer
GOG-0205 – A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva
GOG-0207 – A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3)(IND #69,656, Sponsor – GOG)
GOG-0209 – Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients With Stage III & IV or Recurrent Endometrial Cancer
GOG-0210 – A Molecular Staging Study of Endometrial Carcinoma
GOG-0212 – A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND #70177) Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
GOG-0213 – A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer.
GOG-0215 – A Phase II Randomized Study of the Effect of Zoledronic Acid Versus Observation on Bone Mineral Density of the Lumbar Spine in Women Who Elect to Undergo Surgery That Results in Removal of Both Ovaries
GOG-0218 – A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC #704865, IND #7921) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV, Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
GOG-0219 – A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine (IND #46525) and Radiation in Stage IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis
GOG-0221 – Glycoprotein and Glycan Profiling in Patients With Locally Advanced Cervical Cancer (Stage IB2, IIA > 4cm, IIB to IVA) Undergoing Pelvic and Para-Aortic (Abdominal) Lymphadenectomy
GOG-0222 – Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer
GOG-0232C / BIPAR #20070103 – A Phase II Evaluation of Paclitaxel (Taxol®, NSC #673089), Carboplatin (Paraplatin®, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
GOG-0235 – A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy
GOG-0238 – A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
GOG-0242 – A Phase II Study to Determine the Response to Second Curettage as Initial Management For Persistent Low Risk, Non-Metastatic Gestational Trophoblastic Neoplasia
Drug Company Clinical Trials that are Open at Site but Closed to Accrual:
ABA-01 – A Randomized, Double Blind, Placebo Controlled Multicentre Trial of Abagovamab Maintenance Therapy in Patients with Epithelial Ovarian Cancer after Complete Response to First Line Chemotherapy
CEPO906A2303 – A Randomized, Parallel Group, Open-Label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Lipsomal Doxorubicin (Doxil/Caelyx) in Taxane/Platinum Refractory/Resistant Patients with Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer
CEPO906A2203 – An Open-Label Phase I/II Dose Escalation Study Evaluating the Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian or Primary Peritoneal Cancer
NV06-0039 – A Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol (Oral Dosage Form) in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy
AVF4095g – A Phase II, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma